Sucroferric oxyhydroxide

Sucroferric oxyhydroxide is a medicine used to help lower phosphate levels in people with advanced chronic kidney disease who require dialysis. This page provides information on the use and management of sucroferric oxyhydroxide as part of the treatment of phosphate imbalance associated with kidney disease.

The prescribing guidance, formularies, pathways and information on this website have transferred from the predecessor organisations that now form NHS Central East ICB.

Guidance may not be available for all clinical topics or geographic areas. Where guidance is available, it is clearly identified as applying to Bedfordshire, Luton and Milton Keynes (BLMK), Cambridgeshire and Peterborough (C&P), Hertfordshire or Central East (CE).

Guidance labelled Central East (CE) has been harmonised and approved for use across NHS Central East ICB. Where CE guidance is not available, local arrangements for BLMK, C&P or Hertfordshire remain in place.

For Hertfordshire prescribing guidance, please visit: www.hweclinicalguidance.nhs.uk

Bedfordshire, Luton and Milton Keynes

The Shared Care Guideline below was developed by Hertfordshire and West Essex and has been ratified for use in Bedfordshire, Luton and Milton Keynes for patients receiving care from East and North Hertfordshire Teaching NHS Trust.

Sucroferric oxyhydroxide (oral) for hyperphosphataemia in adult patients with end stage renal failure requiring renal replacement therapy – Shared Care Guideline (pdf)